Company Update (NYSE:BMY): Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial

[Business Wire] – Bristol-Myers Squibb Company today announced that Opdivo is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care in an open-label, randomized Phase III study evaluating previously-treated . . . → Read More: Company Update (NYSE:BMY): Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial Similar Articles: Market Update (NYSE:BMY): U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma Stock Update (NYSE:BMY): Roche open to alliances in hunt for cancer drug combinations